BARICITINIB

baricitinib 4 mg tablet, 28

BARICITINIB (11443G)

baricitinib 4 mg tablet, 28
11443G
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 28 # of repeats: 5 DPMQ: $1,046.34 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Olumiant